Business News • PR NewsWire • Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strains Release of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants of concern and...

View More : https://www.prnewswire.com:443/news-releases/clover-biopharmaceuticals-completes-enrollment-of-adult-and-elderly-populat...

Releted News by prnewswire

Insights on the Car Rental Global Market to 2026 - by Booking, Rental Length, Vehicle Type, Application, End-user and Region

Energy Transitions Commission Warns Demand For Biomass Likely To Exceed Sustainable Supply

Casino Group Partners With Accenture and Google Cloud to Accelerate its Digital Strategy

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

Worldwide Mobile Robots Industry to 2026 - by Type, Component, End-users and Geography

Genpact Named a Leader in Content Moderation Services by Everest Group